3L17

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Changes made to a PDB entry after its initial release are considered to be either “major” or “minor”. The latest minor version of each major version is available as a file download. More information about the PDB versioning is available.

Version Number	Version Date	Version Type/Reason	Version Change	Revised CIF Category
1.0	2010-02-16	Initial release
1.1	2011-07-13		Advisory, Version format compliance
1.2	2017-11-01		Refinement description	software
1.3	2023-09-06		Data collection, Database references, Derived calculations, Refinement description	chem_comp_atom, chem_comp_bond, database_2, pdbx_initial_refinement_model, struct_ref_seq_dif, struct_site	Download

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.